Silver Spike Acquisition Corp II is a blank check company that focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, and similar business combination with one or more businesses or entities. The company was founded in 2020 and is based in New York, New York.
IPO Year: 2021
Exchange: NASDAQ
Website: silverspikecap.com/spkb-spac
| Date | Price Target | Rating | Analyst |
|---|
Fastest customizable press release news feed in the world
NEW YORK, March 13, 2023 (GLOBE NEWSWIRE) -- Silver Spike Acquisition Corp II (the "Company") today announced that it will redeem all of its outstanding Class A ordinary shares (the "Class A Ordinary Shares"), effective as of March 27, 2023, because the Company will not consummate an initial business combination within the time period required by its amended and restated memorandum and articles of association (the "Articles"). As stated in the Company's Articles, if the Company does not consummate an initial business combination within 24 months of the closing of the Company's initial public offering, or March 15, 2023, the Company will: (i) cease all operations except for the purpose of
Eleusis, a clinical-stage life science company that aims to unlock the therapeutic potential of psychedelics, and Silver Spike Acquisition Corp. II ("Silver Spike II" or "SPKB") (NASDAQ:SPKB), a publicly traded special purpose acquisition company ("SPAC"), today announced that they have mutually agreed to terminate their previously announced agreement and plan of merger (the "Business Combination Agreement"), effective immediately, as a result of current unfavorable market conditions. Silver Spike II intends to continue in its efforts to identify a prospective target business for an initial business combination. Additional information about the termination of the Business Combination Agre
Eleusis Holdings Ltd announced today it has received a Notice of Allowance for its proprietary psilocin salt form and accompanying formulations from the US Patent and Trademark Office. This salt form and formulations are being developed as Eleusis' lead drug candidate, ELE-Psilo. ELE-Psilo is an investigational psychedelic drug candidate designed to deliver psilocybin's active moiety, psilocin, by intravenous administration. Psilocybin is a prodrug found naturally in certain species of fungi that is metabolized into its pharmacologically active form, psilocin. Eleusis is developing its proprietary salt form of psilocin to enable practical delivery of psilocin directly, and in the case of E
Business combination with Silver Spike Acquisition Corp. II (NASDAQ:SPKB) expected to generate gross proceeds of up to $288 million and implies a combined enterprise value of $446 million Eleusis pioneers the development of psychedelic drug candidates in the life sciences space, with the goal of transforming psychedelics into broadly accessible medicines Eleusis designed ELE-Psilo, a proprietary psilocybin-based drug candidate that is formulated for IV infusion and in development for the treatment of depression ELE-Psilo program expected to enter clinical trials in Q2 2022 and to target the pressing need for rapid-acting antidepressants compatible with existing healthcare infrastruct
15-12G - Silver Spike Acquisition Corp II (0001826435) (Filer)
25-NSE - Silver Spike Acquisition Corp II (0001826435) (Subject)
8-K - Silver Spike Acquisition Corp II (0001826435) (Filer)
8-K - Silver Spike Acquisition Corp II (0001826435) (Filer)
8-K - Silver Spike Acquisition Corp II (0001826435) (Filer)
DEF 14A - Silver Spike Acquisition Corp II (0001826435) (Filer)
PRE 14A - Silver Spike Acquisition Corp II (0001826435) (Filer)
10-Q - Silver Spike Acquisition Corp II (0001826435) (Filer)
8-K - Silver Spike Acquisition Corp II (0001826435) (Filer)
10-Q - Silver Spike Acquisition Corp II (0001826435) (Filer)
This live feed shows all institutional transactions in real time.
SC 13G - Silver Spike Acquisition Corp II (0001826435) (Subject)
SC 13G/A - Silver Spike Acquisition Corp II (0001826435) (Subject)
SC 13G/A - Silver Spike Acquisition Corp II (0001826435) (Subject)
SC 13G/A - Silver Spike Acquisition Corp II (0001826435) (Subject)
SC 13G/A - Silver Spike Acquisition Corp II (0001826435) (Subject)
SC 13G - Silver Spike Acquisition Corp II (0001826435) (Subject)
SC 13G - Silver Spike Acquisition Corp II (0001826435) (Subject)
SC 13G - Silver Spike Acquisition Corp II (0001826435) (Subject)
SC 13G/A - Silver Spike Acquisition Corp II (0001826435) (Subject)
SC 13G - Silver Spike Acquisition Corp II (0001826435) (Subject)